DOTATATE PET for Meningioma Radiation Planning
ConditionMeningioma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBritish Columbia Cancer Agency
About this trial
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years old
Able and willing to comply with the study procedures
Intact meningioma requiring definitive radiation
Post-operative meningioma requiring adjuvant radiation
Disqualifiers
Breastfeeding or pregnancy
Claustrophobia or inability to lie still in a supine position
Unwillingness or inability to provide informed consent
Trial design
Design model
Single group
Treatments tested in this trial
DOTATATE-PET scan
Diagnostic testDOTATATE tracer PET scan for meningioma
Treatment groups
36 Participants
are divided into 1 treatment groupGroup A: DOTATATE-PET scanExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Target radiation volume
The volume of gross total volume (GTV), clinical target volume (CTV), planned target volume (PTV) contours, and volume of dose exposure to normal brain tissue using standard imaging and DOTATE-PET scan
Time frame
2 yearsSecondary outcomes
1
Local control
Time frame
2 years2
Progression-free survival
Time frame
2 years3
Perceived usefulness by radiation oncologist
Time frame
2 years4
Adverse event
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: